Toxusa Labs LLC

Toxusa Labs LLC was paid $9.62M by Medicaid between Jan 2018 and Dec 2024, across 149 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 23% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Indiana

Rank by total paid#5 of 66

Median peer was paid$53K

This provider vs. median183×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	992	$13K
2019	56,560	$382K
2020	94,554	$2.15M
2021	86,605	$1.23M
2022	90,619	$1.92M
2023	108,632	$2.53M
2024incomplete	43,394	$1.40M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	23%	38,700	24,301	$2.26M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	19%	31,605	22,017	$1.82M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.3%	34,111	23,730	$794K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	6.8%	9,781	7,698	$654K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	6.1%	7,343	5,961	$587K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	4.8%	13,106	9,965	$467K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.7%	15,322	14,029	$265K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.3%	17,577	11,538	$225K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.9%	1,118	1,023	$184K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.1%	3,810	3,333	$103K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,437	1,335	$93K
80354		<1%	9,858	6,993	$83K

137 more codes

80346		<1%	9,861	$83K
80358		<1%	9,848	$78K
80348		<1%	9,867	$78K
80364		<1%	9,841	$73K
87653		<1%	5,575	$72K
80365		<1%	9,842	$70K
87641		<1%	5,058	$65K
80324		<1%	9,872	$64K
87500		<1%	4,823	$59K
80353		<1%	9,839	$58K
80356		<1%	3,905	$53K
80338		<1%	7,864	$51K
87640		<1%	6,123	$50K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	3,238	$50K
87486		<1%	3,294	$49K
87581		<1%	3,281	$49K
87541		<1%	2,908	$48K
80355		<1%	8,198	$47K
80360		<1%	8,258	$45K
87481		<1%	3,940	$43K
80357		<1%	7,796	$42K
80359		<1%	5,479	$41K
80366		<1%	8,156	$35K
80373		<1%	8,160	$33K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,947	$32K
83992		<1%	8,286	$32K
80323		<1%	4,572	$30K
87631		<1%	522	$30K
80345		<1%	5,263	$29K
87150		<1%	339	$28K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,541	$26K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	281	$25K
80335		<1%	3,580	$25K
80368		<1%	7,975	$24K
80361		<1%	4,326	$24K
80332		<1%	4,327	$24K
80337		<1%	4,326	$24K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	662	$19K
80370		<1%	3,670	$18K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,121	$18K
87563		<1%	1,655	$18K
80350		<1%	2,854	$17K
80050	General health panel	<1%	1,488	$17K
80321		<1%	4,341	$16K
80376		<1%	4,319	$16K
87529		<1%	1,150	$14K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,772	$14K
80329		<1%	4,326	$14K
80349		<1%	3,050	$14K
80061	Lipid panel	<1%	2,594	$13K
87483		<1%	489	$11K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	277	$9K
83970		<1%	900	$9K
80372		<1%	4,316	$7K
82607		<1%	1,688	$7K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	180	$6K
80369		<1%	4,315	$6K
84402		<1%	904	$6K
82627		<1%	931	$6K
84403		<1%	969	$6K
87181		<1%	1,046	$6K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,082	$5K
82670		<1%	945	$5K
84144		<1%	936	$5K
87511		<1%	721	$5K
84270		<1%	924	$5K
83001		<1%	931	$5K
80367		<1%	4,317	$5K
83002		<1%	938	$5K
80305		<1%	555	$4K
82533		<1%	938	$4K
82746		<1%	1,222	$4K
82728		<1%	1,196	$4K
84481		<1%	804	$4K
84439		<1%	1,187	$4K
86376		<1%	1,104	$4K
87186		<1%	334	$3K
80053	Comprehensive metabolic panel	<1%	1,131	$3K
87505		<1%	277	$3K
84146		<1%	548	$3K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	318	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,286	$2K
83735		<1%	1,215	$2K
86277		<1%	522	$2K
86352		<1%	28	$2K
83540		<1%	1,223	$2K
87652		<1%	522	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	701	$2K
87497		<1%	182	$2K
87184		<1%	330	$2K
87496		<1%	286	$2K
87081		<1%	693	$1K
86780		<1%	626	$1K
84153		<1%	196	$1K
83003		<1%	328	$1K
87498		<1%	394	$1K
87110		<1%	333	$941.90
86328		<1%	23	$904.60
87070		<1%	330	$800.56
86696		<1%	68	$694.61
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	50	$569.39
87427		<1%	333	$480.78
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	28	$458.80
86695		<1%	81	$451.81
86403		<1%	512	$448.53
87140		<1%	333	$414.53
87850		<1%	28	$340.77
87086	Culture, bacterial; quantitative colony count, urine	<1%	68	$310.91
87510		<1%	28	$300.78
86038		<1%	43	$286.06
83525		<1%	57	$279.01
84480		<1%	45	$243.90
80069		<1%	41	$149.52
87046		<1%	30	$145.60
86592		<1%	73	$125.53
84436		<1%	26	$104.91
82172		<1%	25	$97.60
86431		<1%	33	$91.97
81001		<1%	212	$91.41
84466		<1%	27	$72.76
82977		<1%	39	$72.62
82248		<1%	59	$67.14
86800		<1%	18	$66.50
86141		<1%	25	$50.96
82043		<1%	26	$41.26
84550		<1%	41	$34.37
82150		<1%	24	$29.96
82570		<1%	25	$29.49
80048	Basic metabolic panel (calcium, ionized)	<1%	25	$27.91
84100		<1%	29	$26.92
80076		<1%	26	$24.00
85652		<1%	14	$23.26
86580		<1%	50	$17.00
82950		<1%	13	$12.56
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	0%	28	$0.00
86480		0%	23	$0.00
87503		0%	28	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKHADR, EYAD (OWNER)